These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 8139589)

  • 1. Temporary symptom worsening caused by manidipine hydrochloride in two patients with Parkinson's disease.
    Nakashima K; Shimoda M; Kuno N; Takahashi K
    Mov Disord; 1994 Jan; 9(1):106-7. PubMed ID: 8139589
    [No Abstract]   [Full Text] [Related]  

  • 2. Parkinson's disease.
    Barboi AC; Goetz CG
    Clin Neuropharmacol; 1999; 22(4):184-91. PubMed ID: 10442246
    [No Abstract]   [Full Text] [Related]  

  • 3. A hospital-based study: risk factors in development of motor complications in 555 Parkinson's patients on levodopa therapy.
    Benbir G; Ozekmekçi S; Apaydin H; Delil S; Erginöz E
    Clin Neurol Neurosurg; 2006 Dec; 108(8):726-32. PubMed ID: 16564615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does fluoxetine aggravate Parkinson's disease? A pilot prospective study.
    Montastruc JL; Fabre N; Blin O; Senard JM; Rascol O; Rascol A
    Mov Disord; 1995 May; 10(3):355-7. PubMed ID: 7651460
    [No Abstract]   [Full Text] [Related]  

  • 5. Treatment of drug-induced psychosis in Parkinson's disease with ziprasidone can induce severe dose-dependent off-periods and pathological laughing.
    Schindehütte J; Trenkwalder C
    Clin Neurol Neurosurg; 2007 Feb; 109(2):188-91. PubMed ID: 16949733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Parkinson's disease.
    Clarke C; Moore AP
    Clin Evid; 2002 Jun; (7):1208-20. PubMed ID: 12230738
    [No Abstract]   [Full Text] [Related]  

  • 7. Parkinson's disease.
    Clarke C; Moore A
    Clin Evid; 2002 Dec; (8):1370-85. PubMed ID: 12603943
    [No Abstract]   [Full Text] [Related]  

  • 8. Efficacy and tolerability of manidipine hydrochloride in the long-term treatment of mild-moderate hypertension. Manidipine Efficacy in Long-Term Treatment Group.
    Fogari R; Zoppi A; Lusardi P; Mugellini A
    Blood Press Suppl; 1996; 5():24-8. PubMed ID: 8973789
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Future strategies for the treatment of Parkinson's disease.
    Fahn S
    Adv Neurol; 1993; 60():636-40. PubMed ID: 8420202
    [No Abstract]   [Full Text] [Related]  

  • 10. [Epidemiology and therapy of Parkinson disease in inpatient nursing homes].
    Evers S; Obladen M
    Z Gerontol; 1994; 27(4):270-5. PubMed ID: 7975818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Computational analysis of open loop handwriting movements in Parkinson's disease: a rapid method to detect dopamimetic effects.
    Eichhorn TE; Gasser T; Mai N; Marquardt C; Arnold G; Schwarz J; Oertel WH
    Mov Disord; 1996 May; 11(3):289-97. PubMed ID: 8723147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Case studies in the advancement of Parkinson's disease.
    Frei K; Truong DD; Wolters E
    CNS Spectr; 2008 Dec; 13(12 Suppl 18):1-6. PubMed ID: 19179948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment challenges in early stage Parkinson's disease.
    Tetrud J
    Neurol Clin; 2004 Oct; 22(3 Suppl):S19-33. PubMed ID: 15501364
    [No Abstract]   [Full Text] [Related]  

  • 14. Ethosuximide and tremor in Parkinson's disease: a pilot study.
    Pourcher E; Gomez-Mancilla B; Bédard PJ
    Mov Disord; 1992; 7(2):132-6. PubMed ID: 1350060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of quetiapine on psychosis and motor function in parkinsonian patients with and without dementia.
    Reddy S; Factor SA; Molho ES; Feustel PJ
    Mov Disord; 2002 Jul; 17(4):676-81. PubMed ID: 12210856
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The clinical features of Parkinson's disease in 100 histologically proven cases.
    Hughes AJ; Daniel SE; Lees AJ
    Adv Neurol; 1993; 60():595-9. PubMed ID: 8420197
    [No Abstract]   [Full Text] [Related]  

  • 17. Rating impairment and disability in Parkinson's disease: evaluation of the Unified Parkinson's Disease Rating Scale.
    van Hilten JJ; van der Zwan AD; Zwinderman AH; Roos RA
    Mov Disord; 1994 Jan; 9(1):84-8. PubMed ID: 8139609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Electroconvulsive therapy in comorbidity of treatment refractory paranoid hallucinatory psychoses with Parkinson disease].
    Höflich G; Burghof KW; Kasper S; Möller HJ
    Nervenarzt; 1994 Mar; 65(3):202-5. PubMed ID: 7909917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sleep complaints and their relation with drug treatment in patients suffering from Parkinson's disease.
    Gómez-Esteban JC; Zarranz JJ; Lezcano E; Velasco F; Ciordia R; Rouco I; Losada J; Bilbao I
    Mov Disord; 2006 Jul; 21(7):983-8. PubMed ID: 16602112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Parkinson's disease. An overview of treatments and research.
    Tuite PJ
    Minn Med; 2001 May; 84(5):42-7. PubMed ID: 11398632
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.